Form 4: Centene Director Christopher Coughlin Reports Acquisition of 556 Shares and Updated Holdings

Centene Corp Director Christopher J. Coughlin reported the acquisition of 556 shares of common stock at no cost, along with updated direct and indirect beneficial ownership, and details on existing stock options.

Summary

• Christopher J. Coughlin, a Director of Centene Corp (CNC), reported changes in his beneficial ownership.
• On June 30, 2025, Mr. Coughlin acquired 556 shares of Centene Common Stock.
• The acquisition was reported with a price of $0, indicating it was likely a grant or award.
• Following this transaction, Mr. Coughlin directly beneficially owns 11,435.926 shares of Common Stock, which includes 3,579 shares of restricted stock units subject to vesting requirements.
• Additionally, Mr. Coughlin indirectly beneficially owns 30,054 shares through a grantor retained annuity trust for his benefit and his adult children, for which he is the sole trustee.
• Mr. Coughlin also holds a direct common stock option to buy 10,000 shares at an exercise price of $80.57, exercisable from February 7, 2025, and expiring on February 7, 2032.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: A Form 4 filing reporting an insider acquisition, especially at a $0 price (likely a grant), is generally neutral to slightly positive as it indicates continued equity compensation and alignment of interests, but it does not provide significant new operational or financial information.

Positives

• Director Christopher J. Coughlin increased his direct ownership in Centene Corp by acquiring 556 shares of common stock.
• The acquisition at $0 price suggests a grant or award, potentially aligning management incentives with shareholder interests.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan designed to comply with insider trading laws.

Future Outlook

This Form 4 filing primarily reports past insider transactions and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details an insider transaction for Centene Corp, a major player in the managed healthcare industry. Such transactions are routine disclosures and typically reflect individual executive compensation or investment strategies rather than broader industry trends. However, insider buying can sometimes be viewed as a positive signal of management's confidence in the company's future, especially within a competitive and evolving healthcare landscape.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries.
• The acquisition of shares by a director, especially at a $0 price, is a common form of equity compensation or grant, aligning with typical corporate governance practices in large public companies like Centene.
• There are no specific comparable companies or projects mentioned in this filing to assess against industry-specific benchmarks beyond the general practice of executive equity awards.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 30,054 shares is held by a grantor retained annuity trust for the benefit of Mr. Coughlin and his adult children, of which Mr. Coughlin is the sole trustee.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director, particularly through a grant, can be viewed positively as it aligns management's interests with shareholder value creation. The use of a Rule 10b5-1 plan enhances transparency regarding insider trading.
• Employees: No direct impact on employees is indicated by this insider transaction report.
• Customers: No direct impact on customers is indicated by this insider transaction report.
• Suppliers: No direct impact on suppliers is indicated by this insider transaction report.
• Creditors: No direct impact on creditors is indicated by this insider transaction report.

Key Dates

Keywords

Centene Corp, CNC, Form 4, Insider Trading, Stock Acquisition, Director Ownership, Equity Grant, Stock Options, Beneficial Ownership, Rule 10b5-1